A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.


Updates from The Motley Fool

Latest updates on Novavax from Fool.com.  The Fool has written over 200 articles on Novavax.
Why Novavax Stock Spiked Today

Novavax's experimental flu vaccine hit the mark in a combined phase 1/2 trial in older adults.

Is Novavax, Inc. a Buy?

The risks are high for Novavax. But so are the potential rewards.

3 Growth Stocks to Own in 2018

If you're looking for outstanding growth vehicles to own next year, these three biotech stocks ar...

3 Top Stocks Under $10

Hint: Look to the biotech industry for the best bang for the buck.



Stock Performance

View Interactive NVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novavax.
Current Price: $1.64
Prev Close: $1.64
Open: $1.64
Bid: $1.65
Ask: $1.66
Day's Range: $1.60 - $1.68
52wk Range: $0.73 - $2.75
Volume: 947,898
Avg Vol 7,872,367
Market Cap: $513M
P/E (ttm): -2.60
EPS (ttm): ($0.63)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Novavax.
CAPS Rating 2 out of 5
 
304 Outperform
84 Underperform
CAPS All Stars
 
40 Outperform
18 Underperform

How do you think Novavax will perform against the market?



You pick for Novavax is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Stanley C. Erck, CEO

82% Approve

Based on 35 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novavax.

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers